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The idiopathic inflammatory myopathies (IM) represent a heterogeneous group of autoimmune diseases, of which dermatomyosi-
tis (DM), polymyositis (PM), and sporadic inclusion body myositis (IBM) are the most common. The crucial role played by tumor
necrosis factor alpha (TNFα) in the IM has long been recognized. However, so far, 18 other members of the TNF superfamily have
been characterized, and many of these have not yet received the attention they deserve. In this paper, we summarize current
findings for all TNF cytokines in IM, pinpointing what we know already and where current knowledge fails. For each TNF family
member, possibilities for treating inflammatory diseases in general and the IM in particular are explored.
1. Introduction
The idiopathic inflammatory myopathies (IM) are character-
ized by distinct immune eﬀector mechanisms. Dermatomyo-
sitis (DM) is a complement-mediated endotheliopathy asso-
ciated with perimysial inflammation and perifascicular mus-
cle fiber atrophy. In polymyositis (PM) and sporadic inclu-
sion body myositis (IBM), muscle fibers are injured by auto-
aggressive immune cells which predominantly infiltrate the
endomysium [1]. Additional degenerative phenomena occur
in IBM muscle, such as muscle fiber vacuolation and deposi-
tion of β-amyloid and other ectopically localized proteins
[2]. Other less well-delineated IM include myositis-associa-
ted cancer or connective tissue diseases and immune-media-
ted necrotizing myopathy. Macrophages, dendritic cells
(DCs), and T-cells are prominently present in muscle tissues
of the diﬀerent IM. In DM, large numbers of helper T-cells
are found within the perimysial, often perivascular, inflam-
matory infiltrates. In PM and IBM, activated cytotoxic T-cells
surround and invade nonnecrotic muscle fibers, while helper
T-cells are found at more distant parts of the infiltrates.
B-cell-mediated immunity is an important component of
DM/PM pathogenesis, and autoantibodies can be detected
in up to 70% of patients [3]. The most common is Jo-1,
an antihistidyl-tRNA-synthetase, but more autoantibodies
directed against aminoacyl-tRNA-synthetases or other mus-
cle antigens are continuously being described. Autoantibody
profiles are associated with clinical subsets of patients [4]. In
IBM on the other hand, humoral autoimmunity is a more
controversial subject. However, it has been established that
IBM muscle contains large numbers of plasma cells and
an environment permissive of ectopic lymphoneogenesis,
which suggests the possibility of local maturation of B-cells
and autoantibody production. Indeed, a recent report des-
cribes IBM-specific autoantibodies directed against a yet un-
identified muscle antigen [5].
The important role played by cytokines in the IM has
long been recognized [6]. In this respect, a key role for type I
interferon (IFN)-mediated innate immunity has been shown
in DM and PM [7, 8]. In this paper, the tumor necrosis factor
(TNF) family will be systematically overviewed, discussing
current knowledge on their involvement in the IM and ex-
ploring whether they could represent appropriate targets for
future therapeutic intervention. TNF cytokines aﬀect im-
mune cell proliferation, diﬀerentiation, and survival. Up till
now, 19 members have been identified in man, and they
have been assigned systematic names starting from TNFSF1
to TNFSF18 based on the encoding genes. Ectodysplasin A
(EDA) 1 and 2 have not been assigned systematic names and
will not be discussed in this paper. Most TNF members
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are type II transmembrane proteins whose extracellular C-
terminal TNF homology domain can be cleaved oﬀ by spe-
cific metalloproteinases, generating soluble cytokines. The
TNF-like receptors (TNFR) are type I transmembrane pro-
teins of which cystein-rich domains are the hallmark struc-
tural motif [9].
2. TNFSF2—TNFα
TNFα or cachectin, the prototypic member of the TNF fami-
ly, is produced mainly by activated macrophages and T-
cells. TNFα activates T-cells, B-cells, and macrophages and
induces the expression of other cytokines and cell adhesion
molecules through interaction with its receptor TNF-R55
(TNFR1). The alternative receptor TNF-R75 (TNFR2) has
been shown to chiefly function as a concentrator at cellular
surfaces, transferring the cytokine to TNF-R55 [10]. TNFα
augments the activity of nuclear factor-κB (NF-κB) signaling
pathways [11].
In the IM, TNFα is by far the most studied cytokine of
its family. The endomysial and perimysial inflammatory cells
express varying levels, with macrophages being the primary
source of the cytokine. TNFα is also prominently expressed
in blood vessel endothelial cells of DM tissues [12–14]. The
soluble forms of the receptors TNF-R55 and TNF-R75 are
increased in DM/PM sera [15]. TNF-R75 expression is nota-
bly increased near inflammatory infiltrates in all IM and on
the perimysial and perifascicular blood vessel endothelium in
DM even remote from inflammation [12]. Polymorphisms
in the gene encoding TNFα have been linked to either an
increased risk of, or protection against, the development of
juvenile DM [16, 17].
Neutralization of TNFα is eﬃcacious for treating several
autoimmune diseases. The important catabolic role of TNFα
as a regulator of the chronic inflammation associated with
the IM has made it a therapeutic target for these diseases as
well. Fortunately, knocking out TNFα appears relatively safe
and does not seem to hamper skeletal muscle regeneration
[18]. Four agents, that generate excellent results in rheuma-
toid arthritis (RA) and Crohn’s disease, can be considered
for IM patients: (1) a mouse/human chimeric anti-TNFα
monoclonal antibody termed infliximab (Remicade), (2) a
TNFα-neutralizing receptor fusion protein termed etaner-
cept (Enbrel), (3) a humanized anti-TNFα monoclonal anti-
body termed adalimumab (Humira), and (4) the humanized
polyethyleneglycol conjugated Fab′ anti-TNFα fragment cer-
tolizumab pegol (Cimzia). For the first two compounds, re-
ports so far have revealed variable outcomes in IM patients.
Trial results are summarized in Table 1 [19–26]. Several
phase II clinical trials have been started up, but, in general,
studies suﬀer from low inclusion rate and notably high drop-
out rates mostly due to disease deterioration and adverse
events. However, it appears that anti-TNFα treatment could
be of benefit to a subset of IM patients. The identification
of responsive patients remains diﬃcult, as no specific marker
has been identified yet that may predict the therapeutic out-
come.
3. Other TNF Members Already Investigated to
Some Extent in the IM
3.1. TNFSF1/3—LTα/β. Lymphotoxins (LTs) are versatile
cytokines. They are crucial for robust immune responses
and are key elements required for lymphoid organogenesis
and organization. LTα, also termed TNFβ, is secreted as the
homotrimer LTα3, or complexed on the cell surface with LTβ,
predominantly as LTα1β2 heterotrimers. LTα can bind to the
receptor LTβR as well as to the receptors TNFR1 and TFNR2.
LTβ signals through LTβR ligation only.
It appears that LTs are important factors orchestrating
sustained inflammation in the IM. LTα has been implicated
in the cytotoxic response of CD8+ T-cells towards nonnecro-
tic muscle fibers in PM [27]. LTβ is increased in muscle tissu-
es of DM patients, where it localizes to blood vessels and
intramuscular follicle-like structures. The latter contain large
numbers of T-cells, B-cells, and DCs organized in functional
compartments [28]. Recent data also show that LTβmay well
be an early marker for muscle disease [29].
LTs have been pinpointed as important targets for sup-
pressing inflammation in autoimmune diseases. Studies
showed that depletory monoclonal anti-LTα and the receptor
antagonist LTβR:Ig inhibit disease in murine collagen-induc-
ed arthritis [30, 31]. In addition, administering LTβR:Ig inhi-
bited T-cell-driven intestinal inflammation in murine in-
flammatory bowel disease [32]. In human RA, synovial LTα
and LTβ expression is elevated [33], but targeting the expres-
sion by administering LTβR:Ig failed to meet clinical end
points in a phase IIb clinical trial. As TNFα and LTα share
the receptors TNFR1 and TNFR2, strategies targeting these
receptors influence the activities of both cytokines. There-
fore, the therapeutic eﬀects of competitive antagonists of
TNFR1 and TNFR2, namely, etanercept and lenercept, are
presumed to result from combined inhibition of TNFα and
LTα.
3.2. TNFSF4—OX40L. The primary source of the trans-
membrane glycoprotein OX40L, also termed CD252 or
gp34, are antigen presenting cells, and expression is further
induced when B-cells, DCs, T-cells, and macrophages be-
come activated. The cytokine promotes clonal expansion of
T-cells, leading to long-term T-cell survival and enhanced
memory T-cell development. The receptor OX40, also term-
ed CD134, is expressed on activated T-cells, B-cells, and vas-
cular endothelial cells. Proinflammatory cytokines, including
TNFα, can further augment the expression of the receptor.
The OX40/OX40L interaction provides a costimulatory sig-
nal for T-cells and enhances ongoing immune responses
driven by either helper T-cell type 1 (Th1), Th2, or Th17 cells
[34].
OX40 is present on mononuclear cells in the endomy-
sium and at perivascular sites in PM muscle. OX40 positive
cells are mostly CD4+ cells, few are CD8+ cytotoxic T-cells.
Autoaggressive immune cells invading nonnecrotic muscle
fibers are invariably OX40 negative [35]. OX40L expression
has not yet been described in the IM.
Blocking OX40L has produced strong therapeutic eﬀects in
multiple animal models of autoimmune and inflammatory
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Table 1: Tumor necrosis factor inhibitors for treating inflammatory myopathies: published trial results for infliximab and etanercept.
Compound and treatment
regimen
Diagnosis/patients
continued to end point
Follow-up time
Clinical outcome
at end point
Reference
infliximab 6mg/kg 4-weekly or
more frequent
R-JDM/5 32 to 130 weeks I (5/5) [19]
infliximab 10mg/kg (week 0, 2,
6, 14)
R-DM/1
R-PM/4
R-IBM/4
16 weeks
NC (1/1)
I (2/4) W (2/4)
I (1/4) NC (3/4)
[20]
infliximab 10mg/kg (week 0, 2,
4)
R-DM/1
R-PM/1
12 weeks
I (1/1)
I (1/1)
[21]
infliximab 10mg/kg (week 20)
infliximab 10mg/kg (week 14,
18, 22)
R-DM/1
R-PM/1
66 weeks
I (1/1)
I (1/1)
[22]
infliximab 10mg/kg (week 0, 2,
6, 14, 22)
PM/2 26 weeks I (2/2) [23]
infliximab 8mg/kg (week 0, 2, 6) R-DM/1 6 weeks I (1/1)
infliximab 10mg/kg (week 0, 2,
4, 6, 9)
R-PM/1 69 weeks I (1/1) [24]
infliximab 3mg/kg (week 0, 2, 6,
every 8) and etanercept 25mg
twice weekly
R-DM/1
R-PM/2
36 to 96 weeks
PR (1/1)
I (2/2)
[25]
etanercept 25mg twice weekly R-DM/1 56 weeks I (1/1) [26]
Abbreviations: dermatomyositis (DM), improved (I), inclusion body myositis (IBM), juvenile DM (JDM), no change (NC), partial response (PR),
polymyositis (PM), refractory DM/PM/IBM (R-DM/PM/IBM), worsened (W).
disease, which include inflammatory bowel disease [36] and
arthritis [37]. Neutralizing antibodies to OX40L are currently
being tested in phase II clinical trials for treating asthma.
3.3. TNFSF5—CD40L. CD40L, also termed CD154 or gp39,
is expressed by activated T-cells, mainly on the CD4+ subsets.
Its receptor CD40 is present on antigen presenting cells and
on endothelial cells. CD40L positive T-cells activate mono-
cytes and upregulate adhesion molecules and monocyte
chemoattractant protein 1 (CCL2) production by blood
vessel endothelial cells [38].
The CD40/CD40L system seems to be involved in the im-
munopathogenesis of the IM. A subset of inflammatory cells
in IM tissues express CD40L, of which the majority are CD4+
cells. Also, part of themuscle fibers in PM/DM tissues express
CD40. In vitro IFNγ-stimulation of myoblasts induces CD40
expression, leading to increased levels of IL-6, IL-8, IL-15,
and CCL2 [39]. The induction of proinflammatory factors
through the CD40/CD40L system could contribute to T-cell
recruitment and activation found within IM muscle tissues.
CD40L/CD40 interaction engages antigen presenting
cells, provokes B-cell responses and enhances the production
of proinflammatory cytokines, pinpointing the interaction
as an important regulatory mechanism in inflammatory dis-
ease. In murine collagen-induced arthritis, for example, an
agonistic anti-CD40 antibody exacerbates disease [40], while
a blocking anti-CD40L antibody protects against disease
[41]. Phase I and II trials in humans have already been ini-
tiated, testing the eﬀects of a humanized anti-CD40L anti-
body in inflammatory bowel disease [42]. However, the de-
velopment of IDEC-131, another humanized monoclonal
anti-CD40L, is no longer pursued after a placebo-controlled
trial demonstrated no clinical activity in systemic lupus ery-
thematosus (SLE) [43].
3.4. TNFSF6—FASL. FasL is expressed on activated T-cells
and NK-cells. The cytokine comes in a 40 kDa membrane-
bound and a 29 kDa-soluble variant. Its receptor Fas, also
termed CD95 or apoptosis 1 (Apo1), is constitutively expres-
sed on many cell types. An alternative soluble receptor term-
ed decoy receptor 3 (DCR3) has been described, possibly
serving to counteract Fas function. Fas ligation leads to a
conformational change, which causes binding of death do-
main-containing adaptor proteins, subsequently activating
caspases and nucleases.
A role for the Fas/FasL system in muscle damage is sus-
pected. Proinflammatory in vitro conditions have been
shown to induce apoptosis in muscle cells, a process that can
be partially inhibited by an anti-FasL antibody [44]. How-
ever, apoptosis is not a prominent feature of IM, and data
concerning Fas/FasL expression appear somewhat confusing.
FasL was found absent from IM muscle tissue [45] or ex-
pressed only by some T-cells [27, 46]. Fas expression has been
reported with very diﬀerent frequencies, but the sarcolemma
of regenerating muscle fibers seems to represent the main site
of immunoreactivity. Also, some nonnecrotic invaded mus-
cle fibers in PM/IBM and some atrophic perifascicular
muscle fibers of DM are Fas positive [45, 47, 48]. Serological
studies report unchanged FasL levels, while Fas levels were
significantly higher in PM/DM patients compared to normal
controls [49]. The peripheral blood of DM patients contains
significantly lower percentages of regulatory T-cells, but the
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fraction of Fas positive cells is similar, indicating no increased
susceptibility of regulatory T-cells to FasL-mediated apopto-
sis [50].
The involvement of Fas/FasL interactions in human in-
flammatory disease is complex. It has been shown that Fas/
FasL deficiencies are associated with the accumulation of
lymphocytes and establishment of autoimmune disease. In-
deed, a number of inflammatory diseases seem to be asso-
ciated with decreased serum levels of soluble FasL. Adminis-
tering DCs overexpressing FasL resulted in protection against
murine collagen-induced arthritis [51] possibly through
elimination of autoreactive T-cells. Nonetheless, in RA
synovial fluid, increased levels of soluble FasL have been
found [52]. More research is needed to unravel the precise
involvement of the cytokine in human diseases.
3.5. TNFSF7—CD27L. CD27L, also termed CD70, is expres-
sed on T-cells, B-cells, and NK-cells. It is a T-cell costi-
mulatory molecule whose expression is upregulated upon
activation. CD27L regulates the formation of eﬀector and
memory T-cells and induces their secretion of cytokines.
In the B-cell compartment, CD27L promotes diﬀerentiation
into plasma cells and subsequent antibody production, com-
mitment to memory B-cell responses, and the formation of
germinal centers. The receptor CD27 is constitutively ex-
pressed on resting T-cells and is upregulated upon T-cell acti-
vation. In B-cells, CD27 expression is induced by antigen-
receptor activation.
Very limited data is currently available on CD27L ex-
pression in the IM. We do know that unlike in the series of
SLE patients, CD27L is not increased on peripheral CD4+
cells of a single DM patient, who was included as a disease
control in the study [53].
Under physiological conditions, expression of CD27L is
restricted and transient in nature. Thus, CD27L oﬀers a
potential mechanism to selectively target only the activated
cells of the immune system, B-cells in particular, potentially
avoiding generalized immunosuppression and overt toxicity.
Anti-CD27L was found to improve disease and reduce auto-
antibodies in murine collagen-induced arthritis [54].
3.6. TNFSF10—TRAIL. TNF-related apoptosis-inducing
ligand (TRAIL), also termed Apo2L, can be expressed by var-
ious cell types. It binds TRAIL receptors 1 to 4 and osteo-
protegrin (OPG), inducing target cell apoptosis.
Only one report is available that describes TRAIL in PM,
stating thatmany inflammatory cells are TRAIL positive [55].
TRAIL is expressed in the endomysial capillaries of healthy
skeletal muscle and patients alike.
TRAIL potentially dampens autoimmune responses by
silencing autoreactive T-cell populations and, therefore,
could be beneficial to patients suﬀering from inflammatory
diseases. A study showed that a blocking anti-TRAIL mono-
clonal antibody, on the one hand, exacerbates murine experi-
mental autoimmune encephalomyelitis, while recombinant
TRAIL, on the other hand, suppressed disease [56]. Thus,
strategies delivering a soluble TRAIL equivalent may be
eﬀective in suppressing disease episodes. In addition, a hu-
man study identified TRAIL as a prognostic marker for
IFNβ-response in multiple sclerosis (MS). Upregulated con-
centrations of TRAIL in response to IFNβ distinguished drug
responders from nonresponders [57].
3.7. TNFSF11—RANKL. Receptor activator of NF-κB ligand
(RANKL), expressed on the membranes of T-cells, is also
called TNF-related activation-induced cytokine (TRANCE),
OPG ligand (OPGL), or osteoclast diﬀerentiation factor
(ODF). Two putative receptors for RANKL have been pro-
posed, being RANK and OPG. RANK is a transmembrane
receptor present on DCs and T-cells. OPG is a soluble secret-
ed decoy receptor for RANKL. RANKL acts in synergy with
TNFα, activating a cascade of intracellular signaling events
which lead to osteoclast activation.
In mice, RANKL mRNA is expressed in healthy skeletal
muscle [58], which points to a role in normal muscle physi-
ology. A study reported serum RANKL concentrations to be
significantly higher and RANK levels to be significantly lower
in juvenile DM than in healthy age-matched controls [59].
RANKL/RANK is of major pathophysiological impor-
tance in the bone and joint destruction associated with RA
[59], where RANK expression appears to be limited to the
sites of immune reaction. The development of compounds
that mimic OPG action may prevent osteoclast-mediated
bone loss in patients [60]. Denosumab (AMG-162), a mono-
clonal anti-RANKL antibody, is currently being tested for
treating RA.
3.8. TNFSF13—BAFF and APRIL. B-cell activating factor
(BAFF), also termed TNFSF13b or B-lymphocyte stimulator
(BLyS), is expressed on the surface of monocytes, DCs,
and activated T-cells. BAFF binds three receptors: trans-
membrane activator and calcium-modulating cyclophilin
ligand interactor (TACI), BAFF receptor (BAFFR), and B-
cell maturation antigen (BCMA). BAFF is crucial for B-cell
maturation and survival and antibody production by plasma
cells. In addition, BAFF regulates T-cell activation and
diﬀerentiation. A proliferation-inducing ligand (APRIL) or
TNFSF13 is homologous to BAFF and exists only as a
soluble homotrimer. APRIL binds TACI and BCMA and is
important for B-cell development and function [61].
Serological studies have shown that BAFF levels are sig-
nificantly increased in DM patients [62] but not in PM/IBM
[63]. BAFF levels in serum correlated with IL-7, IL-12, and
CXCL10 [64] and with Jo-1 expression, supporting a role for
BAFF in autoantibody production. In addition, BAFF tran-
scripts were found markedly upregulated in muscle extracts
from DM (12-fold), PM (14-fold), and IBM (21-fold) pa-
tients [65]. In DM muscle, BAFF localizes to the muscle
fibers in perifascicular areas [66]. Interestingly, mononuclear
cells infiltrating IMmuscle express IFNα [67], a potent BAFF
inducer. Serum APRIL levels were found unaltered in IM pa-
tients [64].
Blocking BAFF and APRIL potentially diminishes autore-
active B-cells, which would interrupt B-cell diﬀerentia-
tion and prevent autoantibody production. Thus, BAFF
and APRIL represent appropriate targets for intervention
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in autoimmune diseases with an important humoral
pathogenic component. B-cells are especially associated with
DM infiltrates, where IFNα expression could well be the trig-
ger to activate autoantibody production. In addition, diﬀer-
entiated plasma cells can also be encountered in PM/IBM
muscle samples [68].
The anti-BAFF monoclonal antibody belimumab has
been tested in two phase III trials for the treatment of SLE. In
both trials, belimumab met the primary endpoints, showing
significant clinical improvement compared to standard of
care alone. LY2127399, another BAFF neutralizing antibody,
has entered phase II trials for RA. Atacicept, an Ig fusion pro-
tein of the extracellular domain of the TACI receptor that
binds BAFF and APRIL, has currently reached phase II/III
for treating SLE [69].
4. TNF Members Not Yet Explored in IM
4.1. TNFSF8—CD30L. CD30L is expressed on the mem-
branes of activated T-cells, resting B-cells, and monocytes.
Interaction with its receptor CD30, expressed on T-cells,
and B-cells, leads to their proliferation and activation. In
inflammatory diseases, CD30L/CD30 interactions seem to
represent both deleterious and beneficial eﬀects. A blocking
monoclonal anti-CD30L antibody aggravates allograft rejec-
tion in mice by suppressing regulatory T-cell function [70],
while soluble CD30-Ig fusion protein ameliorates murine
experimental colitis through inhibition of Th17 responses
[71]. Elevated levels of soluble CD30 have been observed in
autoimmune diseases such as RA [72] and SLE [73].
4.2. TNFSF9—4-1BBL. 4-1BBL is predominantly expressed
on activated antigen presenting cells and interacts with the 4-
1BB receptor expressed early and transiently on activated T-
cells and on DCs. The 4-1BBL/4-1BB interaction is relevant
to the pathogenesis of inflammatory disease. In sera of RA
patients, soluble 4-1BB and 4-1BBL levels are increased and
correlate with disease severity [74]. Treatment with an
antagonistic anti-4-1BB antibody reduces severity of arthritis
in animal models, ameliorating inflammation, and the asso-
ciated B-cell responses [75].
4.3. TNFSF12—TWEAK. The multifunctional cytokine
TNF-like weak inducer of apoptosis (TWEAK) triggers
multiple and often seemingly conflicting cellular responses,
which range from cell proliferation to cell death. Moreover,
TWEAK signaling through the FN14 receptor [76] has an
impact on normal muscle functioning. In vitro, TWEAK
inhibits the diﬀerentiation of myoblasts to myotubes [77]
and induces the expression of proinflammatory CCL2 [78].
TWEAK knockout mice exhibit augmented muscle tissue
regeneration [79], while overexpression results in inhibited
myofiber regeneration and increased expression of proin-
flammatory cytokines including TNFα, IL-1β, IL-6, and
CCL2 [80–83]. The proinflammatory cytokines inducible
by TWEAK are important regulators of IM [84], which
warrants further exploration. Also, circulating TWEAK levels
are significantly increased in other human autoimmune dis-
eases such as MS and SLE [85]. A TWEAK-neutralizing
monoclonal antibody ameliorates collagen-induced arthritis
in mice, reducing serum and joint CCL2 levels significantly
[86].
4.4. TNFSF14—LIGHT. Lymphotoxin-related inducible lig-
and that competes for glycoprotein D binding to herpes sim-
plex virus entry mediator (HVEM) on T-cells (LIGHT), also
termed LTγ, binds the receptors LTβR, HVEM, and the decoy
receptor DCR3. LIGHT is expressed by activated T-cells and
immature DCs, and is a potent T-cell costimulatorymolecule
[87] with profound eﬀects on T-cell-mediated disease [88].
LIGHT enhances Th1-mediated immune responses and in
vitro strongly induces CXCR3 ligands [89]. The predomi-
nance of Th1-mediated immunity and CXCL10 expression
have been demonstrated in the IM [90]. In synovial tissues
from RA patients, both LIGHT and its receptor HVEM are
expressed by CD68+ macrophages, and their interaction in-
duces the proinflammatory cytokines TNFα, IL-6, and IL-8
[91]. Blocking LIGHT activity significantly reduces graft ver-
sus host disease [92, 93].
4.5. TNFSF15—TL1. TNF-like 1 (TL1), also termed vascular
endothelial growth inhibitor (VEGI), is expressed by macro-
phages, lymphocytes, and plasma cells. TL1 binding enhan-
ces the expression of IFNγ by T-cells [94] and induces apop-
tosis in endothelial cells. TL1 has been implicated in human
inflammatory bowel disease, where it is found to be increased
in macrophages, plasma cells and lymphocytes [95], and TL1
gene variants have been linked to disease susceptibility [96,
97].
4.6. TNFSF18—GITRL. Glucocorticoid-induced TNF re-
ceptor ligand (GITRL), also termed TNF-like 6 (TL6), is ex-
pressed by endothelial cells, DCs, macrophages, and B-cells.
Its receptor GITR is present on naive, activated, and regu-
latory T-cells that, upon ligation, proliferate and produce-
cytokines. In RA, both GITR and GITRL are expressed in
synovial macrophages that, in response to in vitro stim-
ulation with an anti-GITR monoclonal antibody, produce
TNFα, IL-6, IL-8, and CCL2 [98]. Agonistic anti-GITR
monoclonal antibodies exacerbate joint inflammation and
cytokine production [99].
5. Conclusions and Future Prospects
Oral corticosteroids are still standard treatment for DM and
PM, but they come with serious side eﬀect and incomplete
treatment responses. Patients anxiously await more selective
treatment options. Moreover, IBM patients do not respond
to the immunosuppressive and immunomodulatory drugs
currently available. A better understanding of the deleterious
and beneficial eﬀects of the diﬀerent players that make up
the IM muscle microenvironment is necessary to aid the
development of novel routes for therapy. In addition, such
knowledge could provide markers to distinguish potentially
responsive from nonresponsive patients, better predicting
the outcome of costly immune interventions.
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Figure 1: Potential roles for tumor necrosis factor cytokines in the muscle damage associated with dermatomyositis. Based on current know-
ledge, a model is developed describing the possible involvement of tumor necrosis factor (TNF) cytokines in the sustained inflammation
in perifascicular regions of muscle. Activation of the complement system leads to membrane attack complex (MAC) deposition on blood
vessels and subsequent necrosis. Endothelial monocyte chemoattractant protein-1 (CCL2) recruits inflammatory cells that accumulate and
organize in perimysial areas. Lymphocytes organize into functional compartments and produce lymphotoxins (LTs), TNFα and CD40L,
which further recruit responsive immune cells from the circulation, leading to the buildup of perimysial inflammation. Dendritic cells (DCs)
produce IFNα, which stimulates muscle fibers to secrete B-cell activating factor (BAFF). The latter activates B-cells that, in response, begin
to produce autoantibodies. TNFα, mostly produced by Th-cells, provokes muscle fiber atrophy and stimulates major histocompatibility
complex I (MHC-I) and expression of adhesion molecules.
In this paper, we summarized current knowledge on the
involvement of the TNF superfamily of cytokines in IM, find-
ing ourselves humbled by the lack of data regarding some of
them. The TNF cytokines represent plausible therapeutic tar-
gets for the IM, as they are regulators of the complex inflam-
matory cascade that leads to sustained inflammation. For PM
and IBM, limited information is available for TNF cytokines
other than TNFα. However, for DM, a picture is slowly emer-
ging in which TNF cytokines no doubt play a crucial role.
Based on current knowledge, we developed a model des-
cribing the TNF-mediated sequence of events that lead to-
the characteristic muscle damage, being blood vessel loss,
perifascicular muscle fiber atrophy, and inflammation
(Figure 1).
Selectively targeting individual TNF members provides
new promises and opportunities to develop more eﬃcacious
therapies for IM while avoiding the toxicity seen in existing
systemic anti-inflammatory therapeutics.
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